Apotransferrin Modulation of Th1/Th2 Balance for Autoimmune Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases, such as diabetes mellitus type 1, multiple sclerosis, rheumatoid arthritis, and autoimmune hepatitis, often come with toxic side effects and lack effective prevention methods, necessitating a safer and more effective immunomodulatory approach to regulate cytokine balance.
Innovation Solution
Pharmaceutical compositions containing apotransferrin (APOTf) are administered to induce a transition from a T-helper 1 to a T-helper 2 immunological profile, modulating immune responses and reducing cytokine production associated with autoimmune disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant cytokines, cytokine antagonists or cortisone are administered to modulate immune response, then the Th1/Th2 balance is regulated and autoimmune disease progression is controlled, but toxic effects on various body systems occur
Solution Approach 1:
The patent uses apotransferrin as an intermediary substance to modulate the immune response. Instead of directly administering cytokines or immunosuppressants that cause toxicity, apotransferrin acts as a mediator that indirectly regulates the Th1/Th2 balance by influencing immune cell function and cytokine production, thereby achieving disease control without the harmful side effects of conventional treatments
Solution Approach 2:
The patent employs apotransferrin, a naturally occurring protein with short half-life that is rapidly cleared from the body. This allows for repeated administrations without cumulative toxicity, as the substance does not persist in the system. The approach replaces long-acting immunosuppressants with a transiently acting natural protein that can be administered as needed without building up toxic levels
2Reliability
If current immunosuppressive therapies are used to treat autoimmune diseases, then disease progression is controlled, but safety and tolerability are compromised
Solution Approach 1:
The patent leverages the natural physiological role of transferrin in immune regulation. Rather than suppressing the immune system with harmful drugs, the invention harnesses the body's own natural proteins (apotransferrin) that normally regulate immune responses. This converts the potential harm of immune dysregulation into a beneficial therapeutic effect by restoring natural immune balance
Solution Approach 2:
The patent utilizes apotransferrin, a substance that is naturally present in the body and performs immune-regulatory functions as part of normal physiology. By administering this endogenous protein, the treatment allows the body's own natural mechanisms to control the immune response, rather than relying on external pharmacological agents that cause side effects
Data Source
Figure 1~2
Figure 3A~3B
Figure 4~5B
AI summary
The present invention describes pharmaceutical compositions containing APOTf for use in preventing (or delaying the onset) and treating autoimmune diseases. Based on the experimental data obtained, the molecule has the surprising capacity to favourably modify the immune response profile both in vitro and in vivo.